Close Menu

Melissa Lueke, Eric Rasmussen, Bryan Baldasare

Dec 12, 2018

Melissa Lueke, executive VP and CFO at Meridian Bioscience, will retire from her position effective Jan. 1, 2019. Lueke, who has been at Meridian for 20 years, will remain with the firm in a paid financial consulting role with a renewable contract of three years.

Meridian also promoted Eric Rasmussen from his role as EVP of corporate development to the position of EVP, CFO, and principal financial officer, also effective Jan. 1, 2019. Rasmussen was hired by Meridian in June of 2018, and previously served in corporate development and financial leadership roles at Lear Corporation, an automotive seating and electrical systems supplier. Rasmussen has also served on the advisory board of Exploragen, a DNA lifestyle company.

Meridian has also promoted Bryan Baldasare to the role of Chief Accounting Office. Baldasare has been with Meridian since 2000, and most recently served as Senior VP, Corporate Controller and Treasurer.

More Like This

Jun 18, 2019

Don Enns

Microbiome Insights has appointed Don Enns as an independent member to its board of directors. Enns currently serves as VP and head of global drug delivery at Evonik Industries, joining the firm in 2016 with its acquisition of Transferra Nanoscience, where he was president and CEO. Prior to Transferra, Enns served as president and CEO at Cantest before it was acquired by Maxxam Analytics in 2009.

Jun 18, 2019

Francois Martelet

Novigenix has appointed Francois Martelet to its board of directors as a non-executive director. Prior to Novigenix, Martelet recently retired as CEO at NetScientific. As CEO, Francois was chairman of several companies, including Vortex BioSciences, Wanda, Glycotest, and ProAxsis. Martelet has also held several executive positions, such as CEO at Topotarget, and senior level commercial roles at Novartis Pharma and Merck & Company. 

Jun 17, 2019

Stefan Timmerman

Stefan Timmerman has been appointed CFO of Dutch transplantation and companion diagnostics firm Genome Diagnostics. Currently group controller of private equity firm Broadview Holding, Timmerman was previously controller at SNS bank. Before that, he held the same postition at ASN bank. 

Jun 14, 2019

Leena Das-Young

Guardant health said that Leena Das-Young is leaving her position as chief LUNAR officer and general manager at the company for personal reasons. She will continue her service with the firm through June 18, 2019. In connection with her departure, and in exchange for a customary release of claims, Das-Young will be entitled to certain benefits under the company’s executive severance plan, as well as the retention of certain relocation benefits previously provided to her.

Jun 14, 2019

Amelia Warner

Predictive Oncology has appointed Amelia Warner as the interim chief operating officer of its Helomics subsidiary. Prior to joining Helomics, Warner founded Global Specimens Solutions in 2013. Before GSS, Warner served as CEO for Gentris. She has also served as head of clinical pharmacogenomics and clinical specimen management for Merck. In addition, she has served as chair of the Industry Pharmacogenomics Working Group. 

Jun 13, 2019

Bartu Ahiska

Oxford Biodynamics has appointed Bartu Ahiska as senior vice president (commercial) to spearhead commercialization of the company's EpiSwitch technology platform. Ahisku joins OBD from the Knight Cancer Early Detection Advanced Research Center at Oregon Health & Science University in Portland, where he has been the manager of innovation, IP, and and commercialization since 2016. He was a cofounder and remains a non-executive director of Trogenex in San Diego, and was COO and CEO of cloud-computing company Approxy before its acquisition by Numecent.

Jun 12, 2019

Kristiina Vuori

Bionano Genomics has appointed Kristiina Vuori to its board of directors. Vuori is president and a board member of the Sanford Burnham Prebys Medical Discovery Institute (SBP.) She also serves as a professor at SBP's National Cancer Institute-designated Cancer Center. She holds an MD and PhD from Finland's University of Oulu. Her research has helped delineate molecular pathways that regulate cancer cell survival, motility, metastasis, and drug responsiveness. Her molecular characterization of prolyl hydroxylase helped to enable the formation of FibroGen. 

Jun 11, 2019

Thomas Schinecker, Barbara Schädler, Michael Heuer, Stephan Feldhaus, Peter Voser

Thomas Schinecker has been appointed as CEO of Roche Diagnostics and a member of the firm's corporate executive committee, effective August 1. He will succeed Michael Heuer, who is retiring at the end of July. Schinecker is currently head of Centralized and Point of Care Solutions at Roche Diagnostics. Previously, he was general manager for Roche Diagnostics Germany, and before that, he held various management positions in marketing and sales as well as product development at Roche Diagnostics. He holds a PhD in molecular biology from New York University.

Barbara Schädler will become head of group communications and a member of Roche's enlarged Corporate Executive Committee, effective October 1. She will succeed Stephan Feldhaus, who will leave Roche at the end of September. Schädler is currently head of communications and public affairs at E.ON. Previously, she held communications manager positions at Lufthansa, SAP, and the German Federal Ministry of Finance. She holds a master's degree in economics from the University of Mainz.

Peter Voser will step down from the board of directors of Roche at the end of June due to his additional role as interim CEO of ABB.

Jun 11, 2019

Gail Marcus

Binx Health has appointed Gail Marcus to its board of directors. Marcus has held executive positions in a number of healthcare sectors, including services, diagnostics, healthcare provision, and managed care. She held leadership positions at United Healthcare, Cigna, and private equity-backed diagnostic organizations; has an academic appointment at Massachusetts College of Pharmacy and Health Sciences; and serves on the boards of Natera, Cambridge Epigenetix, and Triple S Management, a Blue Cross Blue Shield affiliate in Puerto Rico.

Jun 07, 2019

Hans Bishop, Jennifer Cook, Joshua Ofman, Maykin Ho, Renée Galá

Grail has appointed Hans Bishop as the firm's CEO. He succeeds Jennifer Cook, who has stepped down from the position for family health reasons. Bishop has served on the firm's board of directors since 2018 and will continue serving as its director. Bishop will also continue serving as executive chair of the Sana board of directors, as well as director of Celgene, Agilent Technologies, and Lyell Immunopharma. Bishop founded Juno Therapeutics in 2013 and served as the firm's president and CEO until it was acquired by Celgene in 2018. Prior to Juno, he served as executive in residence at Warburg Pincus. Before Warburg, Bishop served as executive VP and chief operating officer for Dendreon. Prior to Dendreon, he served as president of specialty medicine at Bayer Healthcare, senior VP of global commercial operations at Chiron, and VP and general manager of European Biopharmaceuticals.

Grail has also appointed Joshua Ofman as its chief of corporate strategy and external affairs. Prior to Grail, Ofman most recently served as senior VP of global health policy at Amgen. Before joining Amgen in 2003, Ofman was a member of the academic faculty at the University of California, Los Angeles School of Medicine, Cedars-Sinai Medicine Center. Ofman also served as senior VP of Zynx Health.

Grail has also appointed Maykin Ho to its board as an independent director. Ho is currently a venture partner of Qiming Venture Partners and a member of the Biotech Advisory Panel of the Stock Exchange of Hong Kong. She serves on the board of directors for FibroGen, Agios Pharmaceuticals, Parexel International, the Aaron Diamond AIDS Research Center, and the Institute for Protein Innovation. Ho is a retired partner of the Goldman Sachs Group, where she served as senior biotechnology analyst, co-head of healthcare for global investment research, and advisory director for healthcare investment banking. Before Goldman Sachs, Ho held various managerial positions at DuPont-Merck Pharmaceuticals and DuPont de Nemours & Company.

Grail also announced that Renée Galá has stepped down as the firm's CFO.

Jun 06, 2019

Eric d'Esparbes

Progenity has hired Eric d'Esparbes as its senior VP and CFO. Prior to Progenity, d'Esparbes served as CFO and interim principal executive officer at Innoviva. Before Innoviva, he held roles as CFO at Joule Unlimited, VP of finance at AEI, and CFO for Meiya Power Company. 

Jun 06, 2019

Ronald Andrews

OncoCyte has appointed Ronald Andrews as its CEO, effective July 1. In addition to serving as a board member at OncoCyte, Andrews has over 30 years of experience in the clinical and molecular diagnostics field. OncoCyte's current CEO, William Annett, will remain with the company in an advisory role.

Prior to joining the firm, Andrews was the founder and principal of the Bethesda Group. Before Bethesda, he served as Thermo Fisher Scientific's genetic science division president, where he oversaw the integration of Life Technologies' genetic platform. He also served as president of Life Tech's Medical Science Venture. Before joining Life Tech, Andrews acted as CEO at Clarient (formerly ChromaVision Medical Systems), which was sold to GE Healthcare in 2010. He subsequently served as GE Molecular Diagnostics' CEO until 2011. Andrews also held various senior executive roles at Roche Diagnostics from 2000 to 2004. Andrews served as VP of marketing at Immucor from 1995 to 2000. Prior to Immucor, Andrews spent about 10 years in management positions at Abbott Diagnostics.

Jun 04, 2019

Andrew Quong

Andrew Quong has joined Fluidigm as the company's first-ever chief science officer. Quong was most recently director of strategic scientific initiatives and partnerships at the Frederick National Laboratory for Cancer Research, a National Cancer Institute-sponsored center. Prior to this, Quong was a faculty member in the Department of Cancer Biology at Thomas Jefferson University and the Department of Oncology at Georgetown University. Quong completed his postdoc at the Naval Research Laboratory as a National Research Council Fellow, and received his PhD in physics from the University of California, Irvine.

May 31, 2019

Kevin Conroy, Michelle Griffin

Adaptive Biotechnologies has appointed Kevin Conroy and Michelle Griffin to its board of directors. Board member Arnold Levine has transitioned to the firm's scientific advisory board.

Conroy currently serves as CEO and chairman of Exact Sciences. He has also served as president of Exact Sciences. Prior to joining Exact Sciences, Conroy served as president and CEO of Third Wave Technologies from 2005 to 2008.

Griffin currently serves as a board of director member and audit committee chair for Acer Therapeutics and HTG Molecular Diagnostics. Griffin previously served on the board of directors and audit committee chair for PhaseRx from 2016 to 2018, OncoGenex Pharmaceutics from 2008 to 2011, and Sonus Pharmaceuiticals from 2004 to 2008. She has also served as executive VP of operations and chief financial officer at OncoGenex from 2011 to 2013. She also held the positions of CEO, senior VP, and chief operating officer at Trubion Pharmaceuticals from 2009 to 2010, and acted as the firm's CFO from 2006 from 2009. Griffin also served as senior VP and CFO of Dendreon from 2005 to 2006.

May 30, 2019

Padma Sundar, Kim Dickinson

OncoCyte has appointed Padma Sundar as its senior VP of marketing and market access. The firm has also appointed Kim Dickinson as its VP of clinical operations.

Prior to OncoCyte, Sundar served as VP of strategy and market access at CellMax Life. Before CellMax, she acted as director of marketing at Guardant Health. Prior to Guardant, Sundar served as senior director at Roche Sequencing. She also held the role of senior director for Affymetrix's oncology portfolio.

Before OncoCyte, Dickinson served as VP of research and development and chief pathologist at Biocare Medical. Prior to BioCare, she served as VP of clinical operations at Roche Tissue Diagnostics. She also served as medical director for Laboratory Corporation of America' clinical trials division. Before working at LabCorp, Dickinson acted as medical director at Esoteric Testing. Prior to Esoteric, Dickinson worked at Quest Diagnostics, Citrus Valley Medical Center, and Pioneer Hospital.

The Hill reports President Donald Trump issued an executive directing federal agencies to cut the number of board and advisory committees they have.

The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.

Scientists in Canada are looking to the UK's plan to sequence children with rare conditions for inspiration, the National Post reports.

In PNAS this week: copy number changes arose during polar bear evolution, genomic and transcriptomic analysis of the Siberian hamster, and more.